Cingulate Inc CING
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Shane Schaffer, Cingulate Chairman & CEO to Present “SMART Launch” Approach at Indegene Digital Summit: Rethinking Commercialization for Emerging Pharma
Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness
Cingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301’s Differentiated Pharmacokinetic Profile
Cingulate Gets FDA Request for Updates on ADHD Drug Application
Trading Information
- Previous Close Price
- $4.24
- Day Range
- $4.23–4.34
- 52-Week Range
- $3.16–11.89
- Bid/Ask
- $4.15 / $4.75
- Shares Outstanding
- 14.54M
- Market Cap
- $61.95M
- Volume/Avg
- 104,087 / 120,616
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 14
- Website
- https://www.cingulate.com
Valuation
Metric | CING |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.52 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | CING |
|---|---|
Quick Ratio | 3.30 |
Current Ratio | 3.50 |
Interest Coverage | −14.96 |
Quick Ratio
CING
Profitability
Metric | CING |
|---|---|
Return on Assets (Normalized) | −114.07% |
Return on Equity (Normalized) | −218.25% |
Return on Invested Capital (Normalized) | −123.96% |
Return on Assets
CING
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|rmJBkX | LOCK|HRR^ | $139B | |||
| Moderna Inc MRNA | LOCK|$sX>mv | LOCK|Sb | $103B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|<B%dpx | LOCK|q#GY? | $94B | |||
| argenx SE ADR ARGX | LOCK|^!#<Fxr | LOCK|R%L | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|&D%^Qf< | LOCK|$<g | $47B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|#<%<@R& | LOCK|<q>n> | $30B | |||
| Incyte Corp INCY | LOCK|!?Ql?B | LOCK|^? | $24B | |||
| BioNTech SE ADR BNTX | LOCK|S?Kw?# | LOCK|J# | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|Nky<V?l | LOCK|Btcvx | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|D#gY^c | LOCK|z& | $15B |
United States